Silvan Tuerkcan
Stock Analyst at Citizens JMP
(4.71)
# 762
Out of 5,053 analysts
432
Total ratings
43%
Success rate
16.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FHTX Foghorn Therapeutics | Downgraded: Hold | n/a | $1.95 | - | 5 | Oct 1, 2026 | |
| CLLS Cellectis | Downgraded: Hold | n/a | $1.18 | - | 24 | Sep 15, 2026 | |
| RLAY Relay Therapeutics | Reiterated: Buy | $21 → $26 | $17.98 | +44.61% | 38 | Aug 10, 2026 | |
| TSHA Taysha Gene Therapies | Reiterated: Buy | $8 → $11 | $4.14 | +165.70% | 44 | Jun 23, 2026 | |
| ENGN enGene Therapeutics | Downgraded: Hold | n/a | $1.70 | - | 7 | May 8, 2026 | |
| NTLA Intellia Therapeutics | Reiterated: Buy | $28 → $30 | $12.58 | +138.47% | 45 | Apr 28, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Buy | $86 → $80 | $51.55 | +55.19% | 56 | Jan 30, 2026 | |
| NUVB Nuvation Bio | Reiterated: Buy | $8 → $10 | $4.90 | +104.08% | 6 | Nov 20, 2025 | |
| BNTC Benitec Biopharma | Reiterated: Buy | $20 → $22 | $9.07 | +142.56% | 26 | Nov 4, 2025 | |
| IDYA IDEAYA Biosciences | Reiterated: Buy | $45 | $36.06 | n/a | 4 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $6 | $0.555 | n/a | 12 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $1.90 | n/a | 12 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $6.71 | n/a | 10 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $3.72 | n/a | 29 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $59.82 | n/a | 53 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $3.61 | n/a | 5 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.365 | n/a | 12 | Jun 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $0.305 | n/a | 3 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $19.80 | n/a | 31 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.000001 | n/a | 7 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.75 | n/a | 3 | May 7, 2020 |
Foghorn Therapeutics
Oct 1, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.95
Upside: -
Cellectis
Sep 15, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.18
Upside: -
Relay Therapeutics
Aug 10, 2026
Reiterated: Buy
Price Target: $21 → $26
Current: $17.98
Upside: +44.61%
Taysha Gene Therapies
Jun 23, 2026
Reiterated: Buy
Price Target: $8 → $11
Current: $4.14
Upside: +165.70%
enGene Therapeutics
May 8, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.70
Upside: -
Intellia Therapeutics
Apr 28, 2026
Reiterated: Buy
Price Target: $28 → $30
Current: $12.58
Upside: +138.47%
CRISPR Therapeutics AG
Jan 30, 2026
Reiterated: Buy
Price Target: $86 → $80
Current: $51.55
Upside: +55.19%
Nuvation Bio
Nov 20, 2025
Reiterated: Buy
Price Target: $8 → $10
Current: $4.90
Upside: +104.08%
Benitec Biopharma
Nov 4, 2025
Reiterated: Buy
Price Target: $20 → $22
Current: $9.07
Upside: +142.56%
IDEAYA Biosciences
Oct 13, 2025
Reiterated: Buy
Price Target: $45
Current: $36.06
Upside: n/a
Sep 22, 2025
Reiterated: Buy
Price Target: $12 → $6
Current: $0.555
Upside: n/a
Sep 17, 2025
Reiterated: Buy
Price Target: $13
Current: $1.90
Upside: n/a
Sep 12, 2025
Reiterated: Buy
Price Target: $15
Current: $6.71
Upside: n/a
Aug 15, 2025
Reiterated: Hold
Price Target: n/a
Current: $3.72
Upside: n/a
Jul 29, 2025
Reiterated: Buy
Price Target: $50
Current: $59.82
Upside: n/a
Jun 18, 2025
Reiterated: Buy
Price Target: $6
Current: $3.61
Upside: n/a
Jun 10, 2025
Reiterated: Hold
Price Target: n/a
Current: $0.365
Upside: n/a
Jun 3, 2025
Reiterated: Buy
Price Target: $4
Current: $0.305
Upside: n/a
May 9, 2025
Downgraded: Hold
Price Target: n/a
Current: $19.80
Upside: n/a
Dec 27, 2024
Rated: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
May 7, 2020
Rated: Hold
Price Target: n/a
Current: $2.75
Upside: n/a